15 май 2013 ... Новые молекулы, исследуемые в качестве потенциальных средств для лечения шизофрении На сайте Schizophrenia Research Forum опубликована сводная таблица всех новых молекул, которые.
Reviva Pharmaceuticals, Inc., a privately held drug discovery and development company, today announces top-line results from REFRESH...
Exposing Your Mental Illness in the Workplace. My schizophrenia diagnosis was disclosed via the employee newsletter. In 2004, I had won the...
Phase 2 study to assess the efficacy, safety and tolerability of RP5063 in male and female patients with schizophrenia.
RP-5063, also known as RP-5000, is an investigational atypical antipsychotic which is under development by Reviva Pharmaceuticals for the treatment of schizophrenia and schizoaffective disorder.
The objective of this study is to evaluate the efficacy and safety of RP5063 relative to placebo for the treatment of schizophrenia or schizoaffective disorder.
神分裂症","indication":"Schizophrenia","profile":"A dopamine D2/D3/D4 receptor partial agonist, 5-HT1A/5-HT2A receptor partial agonist, 5-HT6/5-HT7 receptor antagonist potentially for the treatment...
RP5063 Phase 3 trials in schizophrenia measuring cognition outcome are in preparation.
The objective of this study is to evaluate the efficacy and safety of RP5063 relative to placebo for the treatment of schizophrenia or schizoaffective disorder.
Results from the Phase 1 clinical study of RP5063 conducted in the United States in 55 Caucasian and Asian subjects, both healthy volunteers and schizophrenia patients indicated that drug is...
RP-5063, also known as RP-5000, is an investigational atypical antipsychotic which is under development by Reviva Pharmaceuticals for the treatment of schizophrenia and schizoaffective...